Fate Therapeutics Announces Worldwide Collaboration with Janssen for Novel iPSC-derived Cell-based Cancer ImmunotherapiesGlobeNewsWire • 04/02/20
Fate Therapeutics Announces First Patient Treated in First-in-human Clinical Trial of FT596 and Provides Corporate UpdateGlobeNewsWire • 04/02/20
Are Options Traders Betting on a Big Move in Fate Therapeutics (FATE) Stock?Zacks Investment Research • 03/17/20
Fate Therapeutics, Inc. (FATE) CEO Scott Wolchko on Q4 2019 Results - Earnings Call TranscriptSeeking Alpha • 03/03/20
Fate Therapeutics Announces Expansion of FT516 Clinical Investigation and Publication of Preclinical Data in the Journal BloodGlobeNewsWire • 01/13/20
Fate Therapeutics Soars as Much as 45.8% After Giving Investors What They WantedThe Motley Fool • 12/09/19
Fate Therapeutics Announces New Preclinical Data for FT596 Off-the-Shelf, iPSC-derived CAR NK Cell Cancer ImmunotherapyGlobeNewsWire • 12/08/19
Fate Therapeutics Announces Clinical Data from Landmark Phase 1 Studies of First-ever Universal, Off-the-shelf, iPSC-derived NK Cell Cancer Immunotherapy ProgramsGlobeNewsWire • 12/07/19